股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 高视医疗科技有限公司 (於開曼群島註冊成立的有限責任公司) 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02407 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | FF301 本月底法定 ...

Core Viewpoint - Southbound funds have reduced their holdings in Gaoshi Medical (02407.HK) significantly over the past trading days, indicating a potential shift in investor sentiment towards the company [1]. Group 1: Shareholding Changes - On October 14, southbound funds reduced their holdings by 16,300 shares, marking a decrease of 0.25% [2]. - Over the last five trading days, there has been a cumulative net reduction of 80,500 shares, with reductions occurring on all five days [1][2]. - In the last twenty trading days, the total net reduction reached 761,000 shares, with reductions on all twenty days [1]. Group 2: Current Holdings - As of the latest data, southbound funds hold 6,385,300 shares of Gaoshi Medical, which represents 4.31% of the company's total issued ordinary shares [1][2]. Group 3: Company Overview - Gaoshi Medical Technology Co., Ltd. primarily engages in ophthalmic medical services and operates four divisions: self-owned products, distribution, technical services, and others [2]. - The company's products are widely used in various ophthalmic sub-specialties, including fundus diseases, cataracts, glaucoma, refraction, and pediatric ophthalmology [2].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 公司名稱: 高视医疗科技有限公司 (於開曼群島註冊成立的有限責任公司) 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02407 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | 本月底法定/ ...

Core Viewpoint - The renewal of the exclusive agency agreement between Gaoshi Medical and Schwind eye-tech-solutions GmbH signifies a strengthened strategic partnership, enhancing Gaoshi Medical's competitive advantage in the refractive surgery equipment market in China [1] Group 1: Agreement Details - Gaoshi Medical's subsidiary, Shanghai Gaoshi Mingwang Medical Equipment Co., Ltd., has officially renewed its exclusive agency agreement with Schwind eye-tech-solutions GmbH for the Chinese market, including mainland China, Hong Kong, and Macau [1] - The partnership with Schwind, a key supplier since their initial collaboration in 2009, has lasted over 16 years, indicating a stable and long-term relationship [1] Group 2: Market Implications - The renewal of the exclusive agency agreement is crucial for consolidating Gaoshi Medical's competitive edge in the refractive surgery equipment market in China [1]

德国Schwind公司专注于眼科屈光手术设备研发三十余年，是全球领先的准分子激光及飞秒激光技术供 应商之一。其ATOS个性导航飞秒和AMARIS准分子系列产品以创新性、精确性和稳定性着称，在个性 化屈光矫正及角膜手术等领域处於国际领先地位，已广泛应用于全球一百多个国家和地区的临床实践， 得到全球广大屈光手术医生的高度认可。本次与德国Schwind公司续签独家代理协议，将进一步加深双 方的互惠互利合作关系，为集团创造更多潜在业绩增长机会，符合集团及股东整体利益。 格隆汇9月30日丨高视医疗(02407.HK)宣布，公司附属公司上海高视明望医疗器械有限公司于近日正式 与Schwind eye-tech-solutions GmbH(「德国Schwind公司」)续签独家代理协议，继续负责中国市场(含中 国大陆地区、香港特别行政区及澳门特别行政区)的销售、推广及相关服务工作。德国Schwind公司作为 公司最重要的供应商合作伙伴之一，自2009年首次合作以来双方稳定合作已逾16年。本次独家代理协议 的续签，进一步彰显双方长期稳定的战略互信关系，对于巩固集团在中国屈光手术设备市场的竞争优势 具有重要意义。 ...

Core Viewpoint - The renewal of the exclusive agency agreement between GaoShi Medical and Schwind eye-tech-solutions GmbH signifies a strengthened strategic partnership, enhancing the company's competitive position in the refractive surgery equipment market in China [1] Group 1: Partnership Details - GaoShi Medical's subsidiary, Shanghai GaoShi MingWang Medical Equipment Co., Ltd., has officially renewed its exclusive agency agreement with Schwind eye-tech-solutions GmbH for the Chinese market, including mainland China, Hong Kong, and Macau [1] - The partnership with Schwind, a key supplier since 2009, has lasted over 16 years, indicating a stable and long-term collaboration [1] Group 2: Market Implications - The renewal of the exclusive agency agreement is crucial for consolidating the group's competitive advantage in the refractive surgery equipment market in China [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 自願公告 與德國SCHWIND公司續簽獨家代理協議 本公告由高視醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出，以告知本公司股東及潛在投資者有關本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司附屬公司上海高視明望 醫療器械有限公司於近日正式與Schwind eye-tech-solutions GmbH（「德國Schwind 公司」）續簽獨家代理協議，繼續負責中國市場（含中國大陸地區、香港特別行 政區及澳門特別行政區）的銷售、推廣及相關服務工作。德國Schwind公司作為 本公司最重要的供應商合作夥伴之一，自2009年首次合作以來雙方穩定合作已 逾16年。本次獨家代理協議的續簽，進一步彰顯雙 ...

Core Insights - Highsight Medical (02407.HK) reported a revenue of 653 million yuan for the first half of 2025, reflecting a year-on-year growth of 1.7% [1] - The gross profit reached 316 million yuan with a gross margin of 48.3%, an increase of 1.8 percentage points [1] - Net profit surged to 35.9 million yuan, marking a year-on-year increase of 33.5% [1] Group 1: Financial Performance - The increase in gross margin and net profit is attributed to the rise in self-owned product revenue and continuous optimization of the revenue structure [1] - Self-owned business revenue reached 322 million yuan in the first half of 2025, contributing nearly half of the total revenue [2] - Self-owned product revenue was 203 million yuan, up 14.05% year-on-year, with artificial lenses contributing 171 million yuan, a growth of 11.4% [2] Group 2: R&D Investment and Product Development - R&D investment has consistently increased, from 41.09 million yuan in 2022 to 78.42 million yuan in 2024, with 43.4 million yuan spent in the first half of 2025, a 23.6% increase [1] - The proportion of R&D investment relative to self-owned product revenue rose from 13.3% in 2022 to 21.4% in the first half of 2025 [1] - The company has expanded its self-owned product portfolio to 72 items, with self-owned products contributing over 30% of total revenue [1] Group 3: Market Position and Strategy - The domestic market for ophthalmic medical devices, particularly surgical equipment, remains underdeveloped, presenting opportunities for growth [1] - Highsight Medical's dual strategy of "self-research products + high-end agency" supports its stable cash flow and competitive positioning [1] - The company has established a mature sales network covering 51 countries and regions, enhancing its market reach [1]

Major Events - Lai Kai Pharmaceutical-B (02105) reported positive preliminary results from Phase I clinical MAD study, with LAE102 showing encouraging trends in muscle gain and fat loss [1] - Fuhong Hanlin (02696) received FDA approval for the Phase I clinical trial application of HLX13 for first-line treatment of unresectable hepatocellular carcinoma (HCC) patients [1] - Ningmeng Media (09857) has commenced filming the urban medical emotional drama "Asking Heart 2" [1] - CRRC Corporation (01766) and its subsidiaries signed significant contracts totaling approximately 54.34 billion [1] - Heng Rui Pharmaceutical (01276) received approval to conduct clinical trials for SHR-7787 injection, SHR-4849 injection, Bevacizumab injection, and Atezolizumab injection [1] - Hema Medical (03309) entered into a tripartite global licensing and collaboration agreement with Gilead and Hanmi regarding enecuidar [1] - Jinfang Pharmaceutical-B (02595) completed the enrollment of the first patient in the Phase I/II clinical trial of the molecular glue Pan RAS(ON) inhibitor GFH276 for RAS mutant cancer patients [1] - Gao Shi Medical (02407) obtained international certification for its medical device quality management system [1] Operating Performance - Shenzhen Expressway Company (00548) reported toll revenue of 114 million for the Outer Ring project in August [1] - China National Automobile (00026) announced an annual performance with a post-tax loss attributable to shareholders of 185 million HKD, a year-on-year reduction of 29.64% [1] - OKURA HOLDINGS (01655) reported an annual profit attributable to shareholders of 1.342 billion JPY, a year-on-year decrease of 34.34% [1] - Elephant Future Group (02309) disclosed an annual performance with a loss attributable to owners of approximately 314 million HKD, a year-on-year increase of 71.77% [1] - Henghe Group (00513) reported an annual performance with a loss attributable to owners of approximately 259 million HKD, a year-on-year increase of 0.7% [1]

Core Viewpoint - The company has received ISO13485:2016 certification for its medical device quality management system, indicating compliance with international standards in the medical device industry [1] Group 1: Certification Details - The certification was issued by DEKRA, a leading independent certification body, covering the entire process of design, development, production, and sales of intraocular lenses for cataract and presbyopia patients [1] - ISO13485 is recognized by global regulatory bodies such as China's NMPA, EU's CE, and the US FDA, focusing on patient-centered risk management and quality control throughout the product lifecycle [1] Group 2: Implications for the Company - The achievement of this certification demonstrates the company's commitment to enhancing its quality management system and signifies its capability in medical device quality management, risk control, and compliance operations at an international standard [1] - This important qualification lays a solid foundation for the company to further expand into international markets [1]